Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFINITY interferon gamma trial in post-aggression immunosuppression in ICU
2023-506725-11-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-aggressive immunosuppression (PAIS) comparing Imukin with Placebo (2 arms). Primary endpoint: Ventilator-free days alive by day 28. Planned start Feb 2026; status: authorised.
02
Drugs
interferon gamma-1b
03
Conditions
post-aggressive immunosuppression (PAIS)
Beyond the preview
Go deeper on 2023-506725-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506725-11-00.